This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
143
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed using the last observation carried forward (LOCF) procedure, with only post-Baseline values carried forward. Modified Intent-to-Treat (mITT) Population is defined as all randomized participants who received at least 1 dose of study drug, had a Baseline assessment, and had at least 1 post-Baseline assessment, excluding any assessment taken more than 2 days after a dose of study drug
Time frame: Baseline; 6 weeks
Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Daytime SBP to Week 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Muscle Shoals, Alabama, United States
Unnamed facility
Chandler, Arizona, United States
Unnamed facility
Glendale, Arizona, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
DeLand, Florida, United States
Unnamed facility
Fort Lauderdale, Florida, United States
Unnamed facility
Hialeah, Florida, United States
Unnamed facility
Oviedo, Florida, United States
Unnamed facility
Pembroke Pines, Florida, United States
...and 33 more locations
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Daytime DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Nighttime SBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Nighttime DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Sitting Cuff SBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline: 6 weeks
Change From Baseline in Sitting Cuff DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6
A non-parametric analysis was performed for hsCRP parameters. Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. If hsCRP was \<0.2, 0.1 was imputed for analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Total Cholesterol to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Triglycerides (TG) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value. Data was analyzed using non-parametric analysis.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in HDL-C to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Free Fatty Acids (FFA) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Body Weight to Week 6
Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; 6 weeks
Plasma Trough Concentrations of ETC-1002 and Metabolite ESP15228
Plasma trough concentration is defined as the lowest concentration reached before the next dose is administered.
Time frame: Week 2, Week 4 and Week 6